Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Hyperammonemic Coma in an Adult due to Ornithine Transcarbamylase Deficiency
Roberts, Daniel L. , Galbreath, David A., Patel, B. M. , Ingall, Timothy J., Khatib, Amer , Johnson, Daniel J.

Mayo Clinic

Case Reports in Critical Care | February 12, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-4

10.1155/2013/493216 | PMID 24804122 Get It

Objective. To report an unusual cause of coma in an adult.Design. Case report.Setting. University teaching hospital.Patient. A previously healthy 53-year-old man initially presented with altered mental status and progressed to coma. He was found to be substantially hyperammonemic and did not improve with lactulose therapy and continuous venovenous hemodialysis.Results. Biochemical testing revealed previously undiagnosed ornithine transcarbamylase deficiency, and the patient responded to arginine, sodium phenylacetate, and sodium benzoate.Conclusion. Even in adult patients with no known history, inborn errors of metabolism must be considered in the differential diagnosis of unexplained coma. Defects of the urea cycle can present with an unprovoked hyperammonemic coma.
Sitting and endothelial dysfunction: The role of shear stress
Thosar, Saurabh S. , Johnson, Blair D. , Johnston, Jeanne D., Wallace, Janet P., Johnson, Blair D

Mayo Clinic

Medical Science Monitor | February 6, 2013 | Volume: 18 | Issue: 12 | Pages: RA173-RA180

10.12659/msm.883589 | PMID 23197245 Get It

Single-Use Instrumentation, Cutting Blocks, and Trials Decrease Contamination during Total Knee Arthroplasty: A Prospective Comparison of Navigated and Nonnavigated Cases
Johnson, Aaron J. , Issa, Kimona , Pivec, Robert, Blasser, Kurt, McQueen, David A., Puri, Lalit , Dethmers, Daniel A., Miller, David B. , Ireland, Philip H. , Shurman, John R, Bonutti, Petter, Mont, Michael A.

Mayo Clinic

Journal of Knee Surgery | January 29, 2013 | Volume: 26 | Issue: 04 | Pages: 285-290

10.1055/s-0033-1333664 | PMID 23359398 Get It

Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial
Goss, Paul E., Budd, G. Thomas , Rabaglio, Manuela , Ansari, Rafat , Johnson, David B. , Tozer, Richard , D’Souza, David , Chalchal, Haji , Spadafora, Silvana , Stearns, Vered , Perez, Edith A. , Liedke, Pedro Emanuel Rubini , Láng, István, Elliott, Catherine, Chapman, Judy-Anne W., Shepherd, Lois E. , Ingle, James N. , Pritchard, Kathleen I. , Ellis, Matthew J. , Sledge, George W. , Gelmon, Karen A. , Chapman, Judy‐Anne W., Stearns, Vered , Rabaglio-Poretti, Manuela

Mayo Clinic

Journal of Clinical Oncology | January 28, 2013 | Volume: 31 | Issue: 11 | Pages: 1398-1404

10.1200/jco.2012.44.7805 | PMID 23358971 Get It

Purpose In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letrozole. The steroidal inhibitor exemestane is partially non–cross-resistant with nonsteroidal aromatase inhibitors and is a mild androgen and could prove superior to anastrozole regarding efficacy and toxicity, specifically with less bone loss. Patients and Methods We designed an open-label, randomized, phase III trial of 5 years of exemestane versus anastrozole with a two-sided test of superiority to detect a 2.4% improvement with exemestane in 5-year event-free survival (EFS). Secondary objectives included assessment of overall survival, distant disease–free survival, incidence of contralateral new primary breast cancer, and safety. Results In the study, 7,576 women (median age, 64.1 years) were enrolled. At median follow-up of 4.1 years, 4-year EFS was 91% for exemestane and 91.2% for anastrozole (stratified hazard ratio, 1.02; 95% CI, 0.87 to 1.18; P = .85). Overall, distant disease–free survival and disease-specific survival were also similar. In all, 31.6% of patients discontinued treatment as a result of adverse effects, concomitant disease, or study refusal. Osteoporosis/osteopenia, hypertriglyceridemia, vaginal bleeding, and hypercholesterolemia were less frequent on exemestane, whereas mild liver function abnormalities and rare episodes of atrial fibrillation were less frequent on anastrozole. Vasomotor and musculoskeletal symptoms were similar between arms. Conclusion This first comparison of steroidal and nonsteroidal classes of aromatase inhibitors showed neither to be superior in terms of breast cancer outcomes as 5-year initial adjuvant therapy for postmenopausal breast cancer by two-way test. Less toxicity on bone is compatible with one hypothesis behind MA.27 but requires confirmation. Exemestane should be considered another option as up-front adjuvant therapy for postmenopausal hormone receptor–positive breast cancer.
Posterior reversible encephalopathy syndrome and hemorrhage associated with tacrolimus in a pediatric heart transplantation recipient
Loar, Robert W. , Patterson, Marc C. , Driscoll, David J. , Johnson, Jonathan N. , O’Leary, Patrick , Patterson, Marc

Mayo Clinic

Pediatric Transplantation | January 18, 2013 | Volume: 17 | Issue: 2 | Pages: No page available

10.1111/petr.12039 | PMID 23331314 Get It

AbstractPosterior reversible encephalopathy syndrome (PRES) is a disorder characterized by gray and white matter abnormalities in the temporal, parietal, and occipital lobes of the brain. Its etiology has been attributed to renal failure, immunosuppressive drugs such as cyclosporine and tacrolimus, and other potential entities leading to acute hypertension. Clinical findings include headaches, altered mental status, seizures, visual changes, and focal neurologic deficits. We report the case of a child who developed PRES with intracerebral and subarachnoid hemorrhages associated with tacrolimus exposure 10 days after heart transplantation for restrictive cardiomyopathy. The patient initially presented with complex partial seizures, headache, agitation, and hypertension. Head MRI was suggestive of PRES along with intracerebral and subarachnoid hemorrhages. Tacrolimus was discontinued and blood pressure was controlled. The patient's encephalopathy resolved, but he has had ongoing neurologic symptoms secondary to hemorrhage. Generally, PRES is less common in children than in the adult population and is a rare complication of calcineurin inhibitors (CNI). Presentation with secondary hemorrhage also can occur. In children receiving CNIs presenting with new neurologic symptoms, PRES should be considered as prompt discontinuation of the offending agent can induce resolution of symptoms. Children can develop hemorrhage in the context of PRES, leading to increased morbidity.
Second-Trimester Diagnosis of Triploidy: A Series of Four Cases
Johnson, Kirby L., O'Brien, Jonathan, Wick, Myra , Wick, Jo

Mayo Clinic

American Journal of Perinatology Reports | December 31, 2012 | Volume: 03 | Issue: 01 | Pages: 037-040

10.1055/s-0032-1331378 | PMID 23943708 Get It

A Multivariable Index for Grading Exercise Gas Exchange Severity in Patients with Pulmonary Arterial Hypertension and Heart Failure
Kim, Chul‐Ho , Anderson, Steve, MacCarter, Dean, Johnson, Bruce D.

Mayo Clinic

Pulmonary Medicine | December 31, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-10

10.1155/2012/962598 | PMID 23346397 Get It

Patients with pulmonary arterial hypertension (PAH) and heart failure (HF) display many abnormalities in respiratory gas exchange. These abnormalities are accentuated with exercise and track with disease severity. However, use of gas exchange measures in day-to-day clinical practice is limited by several issues, including the large number of variables available and difficulty in data interpretation. Moreover, maximal exercise testing has limitations in clinical populations due to their complexity, patient anxiety and variability in protocols and cost. Therefore, a multivariable gas exchange index (MVI) that integrates key gas exchange variables obtained during submaximal exercise into a severity score that ranges from normal to severe-very-severe is proposed. To demonstrate the usefulness of this index, we applied this to 2 groups (PAH,n=42and HF,n=47) as well as to age matched healthy controls (n=25). We demonstrate that this score tracks WHO classification and right ventricular systolic pressure in PAH (r=0.53and 0.73,P≤0.01) and NYHA and cardiac index in HF (r=0.49and 0.74,P≤0.01). This index demonstrates a stronger relationship than any single gas exchange variable alone. In conclusion, MVI obtained from light, submaximal exercise gas exchange is a useful approach to simplify data interpretation in PAH and HF populations.
Acute Right Ventricular Failure in a Patient with Hepatic Cirrhosis
Soto, Jose Soto , Geiger, Xochiquetzal J., Johnson, Margaret M.

Mayo Clinic

Case Reports in Pulmonology | December 18, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-3

10.1155/2012/127583 | PMID 23316403 Get It

Pulmonary embolic disease is most commonly a manifestation of venous thromboembolism (VTE). However, fat, tumor, and air may all embolize to the pulmonary vasculature and lymphatics resulting in various clinical manifestations. Tumor emboli to small pulmonary vessels and lymphatics can lead to hypoxemic respiratory failure and shock. We present a 62-year-old male with history of mild COPD and end-stage liver disease secondary to hepatitis C admitted due to progressive shortness of breath and hypoxemia who developed shock and right ventricular failure. After a negative evaluation for venous thromboembolic disease, he had progressive respiratory and hemodynamic deterioration despite mechanical ventilation, renal replacement therapy, and vasopressive/inotropic support. Postmortem examination revealed diffuse micronodular moderately differentiated hepatocellular carcinoma (HCC) without a discrete mass, as well as numerous HCC tumor emboli to the lung and focally to the heart, consistent with disseminated hepatocellular tumor microembolism.
Effect of percutaneous atrial septal defect and patent foramen ovale device closure on degree of aortic regurgitation
Loar, Robert W. , Johnson, Jonathan N. , Cetta, Frank , Hagler, Donald J. , Eidem, Benjamin W., Taggart, Nathaniel W. , Cabalka, Allison K. , Taggart, Nathaniel W

Mayo Clinic

Catheterization and Cardiovascular Interventions | December 14, 2012 | Volume: 81 | Issue: 7 | Pages: 1234-1237

10.1002/ccd.24779 | PMID 23239614 Get It

BackgroundIn recent years, percutaneous device closure has become commonplace for treatment of atrial septal defect (ASD) and patent foramen ovale (PFO). However, the effect of device closure on aortic valve regurgitation (AR) has been questioned.ObjectiveThe purpose of this study was to define changes in AR using echocardiography, before and after device closure of ASD or PFO.MethodsWe retrospectively reviewed all patients who had percutaneous device closure of ASD or PFO at our institution between 2005 and 2009. We compared the preprocedure echocardiogram to the most recent follow‐up study. All investigators were blinded to referral diagnosis, patient demographics, and size and type of the device placed. Aortic regurgitation was graded as none/trivial, mild, moderate, or severe.ResultsOverall, 322 patients qualified for inclusion; 204 with PFO and 118 with ASD. Mean age at time of closure was 48 ± 20 years (range 3–85 years). Mean duration of follow‐up was 1.2 years (range 2 months to 5 years). Only two patients (0.6%) demonstrated any appreciable increase in AR severity. However, both of these patients manifested a clinically insignificant change from a trivial to mild grade of aortic regurgitation.ConclusionsPercutaneous device closure of PFO or ASD does not increase the incidence or severity of AR over medium‐term follow‐up. © 2012 Wiley Periodicals, Inc.
A KCNQ1 Mutation Causes a High Penetrance for Familial Atrial Fibrillation
Bartos, Daniel C. , Anderson, Jeffrey , Bastiaenen, Rachel , Johnson, Jonathan N. , Gollob, Michael H. , Tester, David J. , Burgess, Don E. , Homfray, Tessa , Behr, Elijah R. , Ackerman, Michael J. , Guicheney, Pascale , Delisle, Brian P. , Behr, Elijah Raphael , Gollob, Michael H

Mayo Clinic

Journal of Cardiovascular Electrophysiology | December 11, 2012 | Volume: 24 | Issue: 5 | Pages: 562-569

10.1111/jce.12068 | PMID 23350853 Get It

R231H Causes a High Penetrance for Familial AFBackgroundAtrial fibrillation (AF) is the most common cardiac arrhythmia, and its incidence is expected to grow. A genetic predisposition for AF has long been recognized, but its manifestation in these patients likely involves a combination of rare and common genetic variants. Identifying genetic variants that associate with a high penetrance for AF would represent a significant breakthrough for understanding the mechanisms that associate with disease.Method and ResultsCandidate gene sequencing in 5 unrelated families with familial AF identified the KCNQ1 missense mutation p.Arg231His (R231H). In addition to AF, several of the family members have abnormal QTc intervals, syncope or experienced sudden cardiac arrest or death. KCNQ1 encodes the voltage‐gated K+ channel that conducts the slowly activating delayed rectifier K+ current in the heart. Functional and computational analyses suggested that R231H increases KCNQ1 current (IKCNQ1) to shorten the atrial action potential (AP) duration. R231H is predicted to minimally affect ventricular excitability, but it prevented the increase in IKCNQ1 following PKA activation. The unique properties of R231H appeared to be caused by a loss in voltage‐dependent gating.ConclusionsThe R231H variant causes a high penetrance for interfamilial early‐onset AF. Our study indicates R231H likely shortens atrial refractoriness to promote a substrate for reentry. Additionally, R231H might cause abnormal ventricular repolarization by disrupting PKA activation of IKCNQ1. We conclude genetic variants, which increase IKs during the atrial AP, decrease the atrial AP duration, and/or shorten atrial refractoriness, present a high risk for interfamilial AF.